Gabriel G Malouf

List of Publications by Citations

Source: https://exaly.com/author-pdf/8869303/gabriel-g-malouf-publications-by-citations.pdf
Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

73 papers	2,200 citations	29 h-index	46 g-index
88 ext. papers	2,681 ext. citations	5.5 avg, IF	4.53 L-index

#	Paper	IF	Citations
73	Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes. *Oncotarget*, **2014**, 5, 9864-76	3.3	156
72	Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. *Annals of Oncology*, **2010**, 21, 1834-1838	10.3	153
71	Histone deacetylase inhibitors as anti-neoplastic agents. *Cancer Letters*, **2009**, 280, 192-200	9.9	133
70	NRAS mutation is the sole recurrent somatic mutation in large congenital melanocytic nevi. *Journal of Investigative Dermatology*, **2014**, 134, 1067-1074	4.3	109
69	Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell properties. *Scientific Reports*, **2013**, 3, 2687	4.9	94
68	Next-generation sequencing of translocation renal cell carcinoma reveals novel RNA splicing partners and frequent mutations of chromatin-remodeling genes. *Clinical Cancer Research*, **2014**, 20, 4129-40	12.9	89
67	Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. *European Urology*, **2016**, 70, 348-57	10.2	82
66	Transcription factor E3 and transcription factor EB renal cell carcinomas: clinical features, biological behavior and prognostic factors. *Journal of Urology*, **2011**, 185, 24-9	2.5	75
65	Targeting Calcium Signaling Induces Epigenetic Reactivation of Tumor Suppressor Genes in Cancer. *Cancer Research*, **2016**, 76, 1494-505	10.1	68
64	Characterization of long non-coding RNA transcriptome in clear-cell renal cell carcinoma by next-generation deep sequencing. *Molecular Oncology*, **2015**, 9, 32-43	7.9	63
63	Architecture of epigenetic reprogramming following Twist1-mediated epithelial-mesenchymal transition. *Genome Biology*, **2013**, 14, R144	18.3	63
62	Genomic heterogeneity of translocation renal cell carcinoma. *Clinical Cancer Research*, **2013**, 19, 4673-84	12.9	61
61	Low- and high-grade esthesioneuroblastomas display a distinct natural history and outcome. *European Journal of Cancer*, **2013**, 49, 1324-34	7.5	59
60	Long non-coding RNAs in genitourinary malignancies: a whole new world. *Nature Reviews Urology*, **2019**, 16, 484-504	5.5	55
59	Modelling TFE renal cell carcinoma in mice reveals a critical role of WNT signaling. *ELife*, **2016**, 5,	8.9	45
58	Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas. *Histopathology*, **2017**, 70, 1089-1097	7.3	43
57	Expression of human endogenous retrovirus-K is strongly associated with the basal-like breast cancer phenotype. *Scientific Reports*, **2017**, 7, 41960	4.9	42

56	Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. *BJU International*, **2017**, 120, 782-792	5.6	42
55	Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome. *Molecular Cancer Therapeutics*, **2017**, 16, 397-407	6.1	42
54	Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma reveals an endocrine signature. *Hepatology*, **2014**, 59, 2228-37	11.2	42
53	Impact of adjuvant treatment modalities on the management of patients with stages I-II endometrial stromal sarcoma. *Annals of Oncology*, **2010**, 21, 2102-2106	10.3	39
52	Pure and mixed fibrolamellar hepatocellular carcinomas differ in natural history and prognosis after complete surgical resection. *Cancer*, **2012**, 118, 4981-90	6.4	37
51	The epigenome of AML stem and progenitor cells. *Epigenetics*, **2013**, 8, 92-104	5.7	35
50	p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. *Cancer Cell*, **2019**, 35, 204-220.e9	24.3	32
49	Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. *Cancer Cell*, **2020**, 37, 720-734.e13	24.3	32
48	Renal Medullary Carcinoma: Establishing Standards in Practice. *Journal of Oncology Practice*, **2017**, 13, 414-421	3.1	31
47	Prognostic factors and outcome of undifferentiated endometrial sarcoma treated by multimodal therapy. *International Journal of Gynecology and Obstetrics*, **2013**, 122, 57-61	4	31
46	Cancer subtypes classification using long non-coding RNA. *Oncotarget*, **2016**, 7, 54082-54093	3.3	31
45	DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas. *Clinical Cancer Research*, **2016**, 22, 6236-6246	12.9	30
44	Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders **2018**, 6, 159		29
43	Unique Transcriptomic Profile of Collecting Duct Carcinomas Relative to Upper Tract Urothelial Carcinomas and other Kidney Carcinomas. *Scientific Reports*, **2016**, 6, 30988	4.9	27
42	Recommendations for the Management of Rare Kidney Cancers. *European Urology*, **2017**, 72, 974-983	10.2	27
41	The Promise for Histone Methyltransferase Inhibitors for Epigenetic Therapy in Clinical Oncology: A Narrative Review. *Advances in Therapy*, **2020**, 37, 3059-3082	4.1	27
40	Integrated Multi-omic Analysis of Esthesioneuroblastomas Identifies Two Subgroups Linked to Cell Ontogeny. *Cell Reports*, **2018**, 25, 811-821.e5	10.6	25
39	Inactivation and Mutation Drive a Convergence toward Loss of Function of H3K36 Writers in Clear Cell Renal Cell Carcinomas. *Cancer Research*, **2017**, 77, 4835-4845	10.1	23

38	A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer. *Cancer Treatment Reviews*, **2016**, 48, 25-33	14.4	18
37	Stereotactic Radiation Therapy for Renal Cell Carcinoma Brain Metastases in the Tyrosine Kinase Inhibitors Era: Outcomes of 120 Patients. *Clinical Genitourinary Cancer*, **2019**, 17, 191-200	3.3	16
36	Expression of long non-coding RNA MFI2-AS1 is a strong predictor of recurrence in sporadic localized clear-cell renal cell carcinoma. *Scientific Reports*, **2017**, 7, 8540	4.9	16
35	Long non-coding RNA profiling links subgroup classification of endometrioid endometrial carcinomas with trithorax and polycomb complex aberrations. *Oncotarget*, **2015**, 6, 39865-76	3.3	16
34	Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study. *Archives of Cardiovascular Diseases*, **2020**, 113, 9-21	2.7	15
33	Methylome sequencing for fibrolamellar hepatocellular carcinoma depicts distinctive features. *Epigenetics*, **2015**, 10, 872-81	5.7	14
32	Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers. *Scientific Reports*, **2020**, 10, 701	4.9	13
31	Sarcomatoid Dedifferentiation in Renal Cell Carcinoma: From Novel Molecular Insights to New Clinical Opportunities. *Cancers*, **2019**, 12,	6.6	13
30	Therapeutic Strategies for Patients With Metastatic Renal Cell Carcinoma in Whom First-Line Vascular Endothelial Growth Factor Receptor-Directed Therapies Fail. *Journal of Oncology Practice*, **2016**, 12, 412-20	3.1	10
29	Comprehensive integrative profiling of upper tract urothelial carcinomas. *Genome Biology*, **2021**, 22, 7	18.3	10
28	Non-clear cell renal cell carcinomas: biological insights and therapeutic challenges and opportunities. *Clinical Advances in Hematology and Oncology*, **2017**, 15, 409-418	0.6	9
27	Evaluating the prognostic potential of the Ki67 proliferation index and tumour-infiltrating lymphocytes in olfactory neuroblastoma. *Histopathology*, **2019**, 75, 853-864	7.3	8
26	Lack of efficacy of neoadjuvant chemotherapy in adult patients with maxillo-facial high-grade osteosarcomas: A French experience in two reference centers. *Oral Oncology*, **2019**, 95, 79-86	4.4	7
25	Addressing resistance to immune checkpoint inhibitor therapy:an urgent unmet need. *Future Oncology*, **2021**, 17, 1401-1439	3.6	7
24	Oncogenic viruses: Lessons learned using next-generation sequencing technologies. *European Journal of Cancer*, **2016**, 61, 61-8	7.5	7
23	Brain Metastases and Place of Antiangiogenic Therapies in Alveolar Soft Part Sarcoma: A Retrospective Analysis of the French Sarcoma Group. *Oncologist*, **2019**, 24, 980-988	5.7	6
22	French Multidisciplinary Approach for the Treatment of MSK Tumors. *Seminars in Musculoskeletal Radiology*, **2020**, 24, 310-322	1.8	5
21	Dynamic Evolution of Clonal Composition and Neoantigen Landscape in Recurrent Metastatic Melanoma with a Rare Combination of Driver Mutations. *Journal of Investigative Dermatology*, **2019**, 139, 1769-1778.e2	4.3	4

20	Efficacy of Immune Checkpoint Inhibitors in Upper Tract Urothelial Carcinomas: Current Knowledge and Future Directions. *Cancers*, **2021**, 13,	6.6	4
19	Reply to Uncidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomasU *Histopathology*, **2017**, 71, 836-837	7.3	1
18	Molecular profiling of renal medullary carcinoma to reveal frequent alterations in chromatin remodeling genes and to identify EZH2 as a relevant therapeutic target.. *Journal of Clinical Oncology*, **2016**, 34, 571-571	2.2	1
17	Comparative transcriptomic profiling of renal medullary carcinoma (RMC) to determine distinct signatures and pathways associated with response to chemotherapy.. *Journal of Clinical Oncology*, **2018**, 36, 4575-4575	2.2	1
16	Prognostic impact of percentage of squamous differentiation in patients with nonbilharzial squamous cell carcinoma and transitional cell carcinoma treated with radical cystectomy.. *Journal of Clinical Oncology*, **2018**, 36, 498-498	2.2	1
15	Integrative analysis of sarcomatoid clear-cell renal cell carcinomas reveals an immune subgroup.. *Journal of Clinical Oncology*, **2017**, 35, 4571-4571	2.2	1
14	Effect of SMARCB1 deficiency in renal medullary carcinoma (RMC) on genes associated with nucleosome assembly and telomere organization.. *Journal of Clinical Oncology*, **2018**, 36, 614-614	2.2	0
13	Metabolic Response to BRAF-MEK Combination Therapy in Cecal Neuroendocrine Carcinoma With BRAFV600E Mutation and Refractory Lactic Acidosis. *Clinical Nuclear Medicine*, **2018**, 43, 701-702	1.7	0
12	Classifying endometrioid endometrial cancer by long noncoding RNA profiling: Indication of prognosis and therapy selection.. *Journal of Clinical Oncology*, **2014**, 32, 11064-11064	2.2	
11	Comprehensive genomic profiling of renal cell carcinoma with sarcomatoid dedifferentiation to pinpoint recurrent genomic alterations.. *Journal of Clinical Oncology*, **2016**, 34, 537-537	2.2	
10	Translocation Renal Cell Carcinomas **2016**, 41-52		
9	DNA methylation signature to define cell ontogeny of renal cell carcinomas.. *Journal of Clinical Oncology*, **2016**, 34, 536-536	2.2	
8	Assessment of tumor-infiltrating lymphocytes and immune-checkpoints expression in metastatic colorectal cancer patients.. *Journal of Clinical Oncology*, **2016**, 34, 3608-3608	2.2	
7	Comprehensive genomic characterization of clear-cell renal cell carcinomas with sarcomatoid dedifferentiation.. *Journal of Clinical Oncology*, **2016**, 34, e16076-e16076	2.2	
6	Management and outcomes of patients with renal medullary carcinoma (RMC): A collaborative multi-center study of 52 patients.. *Journal of Clinical Oncology*, **2016**, 34, e16111-e16111	2.2	
5	Transcriptomic profiling of collecting duct carcinoma to reveal metabolic and immune aberrations.. *Journal of Clinical Oncology*, **2016**, 34, 4572-4572	2.2	
4	Molecular profiling of renal medullary carcinoma to reveal frequent alterations in chromatin remodeling genes and to identify EZH2 as a relevant therapeutic target.. *Journal of Clinical Oncology*, **2016**, 34, 4566-4566	2.2	
3	DNA methylation profiling of renal cell carcinomas subtypes to identify epi-clusters linked to cell ontogeny.. *Journal of Clinical Oncology*, **2016**, 34, 4512-4512	2.2	

2	Antitumor activity of abiraterone, enzalutamide, and docetaxel following treatment with diethystilbestrol in castration-resistant prostate cancer.. *Journal of Clinical Oncology*, **2017**, 35, e581-e581	2.2
1	Efficacy of additional chemotherapy following failure of currently approved therapies in patients with castration-resistant prostate cancer.. *Journal of Clinical Oncology*, **2017**, 35, 274-274	2.2